A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The effects of fluoxetine and placebo on repetitive behaviors and global severity were compared in adults with autism spectrum disorders (ASDs). METHOD: Adults with ASDs were enrolled in a 12-week double-blind placebo-controlled fluoxetine trial. Thirty-seven were randomly assigned to fluoxetine (N=22) or placebo (N=15). Dosage followed a fixed schedule, starting at 10 mg/day and increasing as tolerated up to 80 mg/day. Repetitive behaviors were measured with the compulsion subscale of the Yale-Brown Obsessive Compulsive Scale; the Clinical Global Impression (CGI) improvement scale was used to rate improvement in obsessive-compulsive symptoms and overall severity. RESULTS: There was a significant treatment-by-time interaction indicating a significantly greater reduction in repetitive behaviors across time for fluoxetine than for placebo. With overall response defined as a CGI global improvement score of 2 or less, there were significantly more responders at week 12 in the fluoxetine group than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: fluoxetine, 35%; placebo, 0%) and 1.8 for CGI-rated improvement in obsessive-compulsive symptoms (responders: fluoxetine, 50%; placebo, 8%). Only mild and moderate side effects were observed. CONCLUSIONS: Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and CGI rating of obsessive-compulsive symptoms, as well as on the CGI overall improvement rating. Fluoxetine appeared to be well tolerated. These findings stand in contrast to findings in a trial of citalopram for childhood autism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A few studies have also focused on the hypothesis that, at the level of neural circuits, ASD may result from excessive excitation or insufficient inhibition 213 , with some promising but inconclusive results for medicines that target the GABAergic system 214 .”
From Autism spectrum disorder (2020) · cites this paper as [213]
In the citing paper
“increased rates of behavioral activation, impulsiveness, and stereotypy have been observed in studies examining the use of SSRIs among patients with ASD for the treatment of restricted and repetitive behaviors [118].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [118]
In the citing paper
“Some trials of SSRIs evaluated depression as a secondary outcome measure, but they did not recruit for clinically significant depression in their participant cohort [118].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [118]
Citations
Cites
Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Leventhal, B. L., DiLavore, P. C., Pickles, A., & Rutter, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005592401947 · Cited by 7,520
Adult outcome for children with autism
Howlin, P., Goode, S., Hutton, J., & Rutter, M. (2004) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2004.00215.x · Cited by 1,813
Autism From 2 to 9 Years of Age
Lord, C., Risi, S., DiLavore, P. S., Shulman, C., Thurm, A., & Pickles, A. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.694 · Cited by 973
The antidepressant fluoxetine restores plasticity in the adult visual cortex
Vetencourt, J. F. M., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., F. O'Leary, O., Castrén, E., & Maffei, L. (2008) · Science · doi:10.1126/science.1150516 · Cited by 890
Mathur, R. (2004) · Drug Screening Methods · doi:10.5005/jp/books/10243_6 · Cited by 665
A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder
McDougle, C. J. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830110037005 · Cited by 556
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Self-citationA Five to Fifteen Year Follow-Up Study of Infantile Psychosis: II. Social and Behavioural Outcome
Rutter, M., Greenfeld, D., & Lockyer, L. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1183 · Cited by 476
Research works printed but not linked: 2
- 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9 · doi:10.1002/1531-8249(199903)45:3<287::aid-ana3>3.0.co;2-9
- Aman MG, 1985, Am J Ment Defic, 89, 485
Cited by
Items 101–200 of 225
Freitag, C. M., & Jarczok, T. A. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1501-5_13 · Cited by 13
Birch, R. C., Foley, K., Pollack, A., Britt, H. C., Lennox, N. G., & Trollor, J. N. (2017) · Autism · doi:10.1177/1362361317714588 · Cited by 19
“There is preliminary evidence that fluoxetine and sertraline may be effective in reducing obsessive-compulsive symptoms in adults with ASD (Hollander et al., 2012; McDougle et al., 1998), and that clonidine may be effective in improving irritability and hyperactivity in children with ASD (Jaselskis…”
BackgroundThorkelson, G., Laughlin, S. F., Turner, K. S., Ober, N., & Handen, B. L. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0001 · Cited by 15
“Among adults with ASD, significant decreases in repetitive thoughts and behaviors have been noted in two placebo-controlled trials (McDougle et al. 1996; Hollander et al. 2012).”
Doyle, C. A., McDougle, C. J., & Stigler, K. A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0506-5_9 · Cited by 13
Myers, S. M., & Challman, T. D. (2018) · American Academy of PediatricsItasca, IL eBooks · doi:10.1542/9781610021357-19 · Cited by 14
Carpita, B., Stagnari, R., Palego, L., Baroni, D., Massimetti, G., Nardi, B., Cremone, I. M., Betti, L., Giannaccini, G., & Dell’Osso, L. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230131115031 · Cited by 12
Yang, P., Menga, Y., Li, T., & Huang, Y. (2017) · Autism Research · doi:10.1002/aur.1822 · Cited by 10
Rai, D., Webb, D., Lewis, A. L., Cotton, L., Norris, J. E., Alexander, R., Baldwin, D. S., Brugha, T. S., Cochrane, M., Piccolo, M. C. D., et al. (2024) · Trials · doi:10.1186/s13063-023-07847-3 · Cited by 15
“To our knowledge, there have been three small RCTs of SSRIs in autistic adults to date [two for fluoxetine with n = 6 [20] and n = 37 [22] participants respectively, and one for fluvoxamine, n = 30 [23]] all with a focus on repetitive behaviours in autistic people.”
BackgroundAmeringen, M. V., Fineberg, N. A., Ravindran, A. V., Arnold, P. D., Beaulieu, S., Brakoulias, V., Brietzke, E. M., Dowlati, Y., Drummond, L. M., Ferretti, C. J., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.039 · Cited by 14
Self-citationAnxiety in Children with Autism Spectrum Disorder
Jennett, H. K., Vasa, R. A., & Hagopian, L. P. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6599-7_16 · Cited by 10
Neurodevelopmental roles and the serotonin hypothesis of autism spectrum disorder
Daly, E., Tricklebank, M. D., & Wichers, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813323-1.00002-5 · Cited by 13
Clinician’s Manual on Autism Spectrum Disorder
Brian, J. A., & Anagnostou, E. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-03056-2 · Cited by 12
Self-citationScahill, L. D., Sukhodolsky, D. G., Anderberg, E., Dimitropoulos, A., Dziura, J. D., Aman, M. G., McCracken, J. T., Tierney, E., Hallett, V., Katz, K. H., et al. (2015) · Autism · doi:10.1177/1362361315574889 · Cited by 11
Whelan, T. P., Daly, E., Puts, N. A. J., Smith, P. L., Allison, C. L., Baron‐Cohen, S., Malievskaia, E., Murphy, D., & McAlonan, G. M. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05768-2 · Cited by 13
Vannucchi, G., Perugi, G., & Masi, G. (2019) · Springer eBooks · doi:10.1007/978-3-030-26276-1_7 · Cited by 9
Stereotyped movement disorder in ICD-11
Stein, D. J., & Woods, D. W. (2014) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2014-3606 · Cited by 8
A review of how psychotropic medication can affect the motivation of challenging behavior
Cox, A. D., & Ortega, J. V. (2016) · International Journal of Developmental Disabilities · doi:10.1080/20473869.2016.1175157 · Cited by 12
“…are often prescribed for depression, OCD, and panic disorders among typically developed individuals (Firestone and Marshall 2007), but among persons with ID antidepressants, they are prescribed to reduce behaviors thought to indicate depression, OCD, and panic disorders (Hollander et al. 2012).”
BackgroundVilela, J. E. R., Martiniano, H., Marques, A. R., Santos, J. X., Asif, M., Rasga, C., Oliveira, G., & Vicente, A. M. (2023) · Biomedicines · doi:10.3390/biomedicines11112971 · Cited by 7
Valdovinos, M. G., Epperson, C., & Johnson, C. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.08.010 · Cited by 8
Özyurt, G., & Beşiroğlu, L. (2017) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.18138 · Cited by 17
Neurodevelopmental Disorders: Autism Spectrum Disorder
Thom, R. P., Friedman, N. D. B., Nasir, R. H., Politte, L. C., Nowinski, L. A., & McDougle, C. J. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_36-1 · Cited by 10
Zheng, J., Chen, J., Zhang, Q., Ying, L., Huang, H., Yang, H. J., & Chen, Z. (2025) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-025-00440-y · Cited by 6
Homicidal Ideation and Individuals on the Autism Spectrum
Frizzell, W., Howard, L., Norris, H. C., & Chien, J. (2019) · Journal of Forensic Sciences · doi:10.1111/1556-4029.14002 · Cited by 6
“Finally, repetitive behaviors, which are a risk factor for violence in ASD, may be treated with SSRIs (47).”
BackgroundNeurodevelopmental Disorders: Autism Spectrum Disorder
Thom, R. P., Friedman, N. D. B., Nasir, R. H., Politte, L. C., Nowinski, L. A., & McDougle, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_36 · Cited by 9
Muneoka, K. T., Kuwagata, M., Ogawa, T., & Shioda, S. (2014) · The Cerebellum · doi:10.1007/s12311-014-0611-2 · Cited by 7
Gannon, S., & Osser, D. N. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112900 · Cited by 7
Freitag, C. M., & Jarczok, T. A. (2016) · Springer eBooks · doi:10.1007/978-3-662-48624-5_13 · Cited by 6
David, A., Stolar, O. E., Berkovitch, M., Kohn, E., Hazan, A., Waissengreen, D., & Gal, E. (2024) · Cannabis and Cannabinoid Research · doi:10.1089/can.2024.0001 · Cited by 8
Mammarella, V., Randazzo, L., Romano, S., Breda, M., & Bruni, O. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2508277 · Cited by 9
Nilles, C., Amorelli, G., Pringsheim, T. M., & Martino, D. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1764164 · Cited by 5
Reviriego, E., Bayón, J. C., Gutiérrez, A., & Galnares-Cordero, L. (2022) · GuíaSalud eBooks · doi:10.46995/ot_3 · Cited by 7
Developmental Fluoxetine Exposure Alters Behavior and Neuropeptide Receptors in the Prairie Vole
Lawrence, R. H., Palumbo, M., Freeman, S. M., Guoynes, C. D., & Bales, K. L. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.584731 · Cited by 7
Current state and future prospects of pharmacological interventions for autism
Vahabzadeh, A. B. N., Buxton, D., McDougle, C. J., & Stigler, K. A. (2013) · Neuropsychiatry · doi:10.2217/npy.13.22 · Cited by 5
Mehta, S., & Golshani, P. (2013) · Neurologic Clinics · doi:10.1016/j.ncl.2013.04.009 · Cited by 6
Emslie, G. J. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010004 · Cited by 5
Martino, D., Espay, A. J., Fasano, A. A., & Morgante, F. (2015) · Springer eBooks · doi:10.1007/978-3-662-48468-5_3 · Cited by 7
Ben‐Sasson, A., & Stephenson, K. G. (2021) · Autism and child psychopathology series · doi:10.1007/978-3-030-66445-9_11 · Cited by 10
Ballenger, J. C. (2012) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/j.ypsy.2012.06.027 · Cited by 4
Serotonin Disturbance in Mouse Models of Autism Spectrum Disorders
Tamada, K., & Takumi, T. (2014) · Neuromethods · doi:10.1007/978-1-4939-2250-5_9 · Cited by 5
A Review of Therapeutic Approaches for Autism Spectrum Disorder
Hai, Y., Bai, S., Qiao, H., Li, D., Wang, D., & Xia, M. (2025) · Brain Sciences · doi:10.3390/brainsci15121280 · Cited by 6
“Antidepressants primarily alleviate symptoms of depression and anxiety by increasing serotonin levels [22,23].”
Kawamoto, A., Kajiume, A., Yoshida, H., Toshima, T., & Kobayashi, M. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.01.007 · Cited by 4
Advances in Genetic Diagnosis of Autism Spectrum Disorders
Shen, J., & Miller, D. T. (2014) · Current Pediatrics Reports · doi:10.1007/s40124-014-0042-z · Cited by 3
Behavioral Treatments for Anxiety in Adults With Autism Spectrum Disorder
White, S. W., Conner, C. M., & Maddox, B. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805122-1.00009-0 · Cited by 3
Pharmacotherapy for bipolar disorder in adults with high-functioning autism
Amadori, S., Barbuti, M., & Perugi, G. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2138332 · Cited by 4
When Genetic and Environmental Factors Meet in Modelling Autism
Pettie, M. A. (2020) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17148212.v1 · Cited by 4
Tarchi, L., Doose, A., Hennig, J., Bernardoni, F., King, J. A., Pisano, T., Castellini, G., Ricca, V., Kamp‐Becker, I., & Ehrlich, S. (2026) · Autism Research · doi:10.1002/aur.70243 · Cited by 2
“Empirical evidence lends support to this assumption, as 5HT1a/5HT4 agonists have been shown to ameliorate co-occurring conditions and potentially target specific domains of distress in AI (Chugani et al. 2016; Ghanizadeh and Ayoobzadehshirazi 2015; Hollander et al. 2012).”
Descriptive Longitudinal Analysis of Stereotypy and Corresponding Changes in Psychotropic Medication
Piersma, D. E., Aguilar, M., Seibert, H. N., Boyle, B., Griffith, G., & Valdovinos, M. G. (2021) · Developmental Neurorehabilitation · doi:10.1080/17518423.2021.2011461 · Cited by 2
“g.(27) the effects observed are marginal, and significant effects are lost when further analyses compensate for publication bias.”
BackgroundA Systematic Approach to Explore the Rigor of Applied Behavioral Pharmacology Research
Khokhar, N., Cox, A. D., & Kozluk, A. (2023) · Review Journal of Autism and Developmental Disorders · doi:10.1007/s40489-023-00400-7 · Cited by 4
“…randomized clinical trials are considered the gold standard for pharmacological evaluation and have been observed in the literature (e.g., Hollander et al., 2012), their appropriateness in some disciplines (e.g., psychological, applied pharmacological assessment) has at times been…”
de Miguel, L., Ballester, P., Egoavil, C. M., de Ocaña‐Moreno, M. L. S., García‐Muñoz, A. M., Cerdá, B., Zafrilla, P., Ramos, E., & Peiró, A. M. (2023) · Pharmaceuticals · doi:10.3390/ph16101496 · Cited by 3
Thom, R. K., Thom, R. P., & McDougle, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-46463-8_9 · Cited by 2
El-Ansary, A. K., AL-Ayadhi, L. Y., Alhakbany, M. A., Polyakova, V., & Suchkov, S. (2024) · International journal for autism challenges & solution. · doi:10.54878/c0yn1911 · Cited by 4
Pharmacotherapy of Anxiety and Repetitive Behaviors in Autism Spectrum Disorders
Propper, L., & Orlik, H. (2014) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.2014.19.1.5 · Cited by 2
Immune Involvement in Autism Spectrum Disorder as a Basis for Animal Models
Hsiao, E. Y. (2012) · Autism - Open Access · doi:10.4172/2165-7890.s1-003 · Cited by 4
Neurological evaluation and management of autism spectrum disorder
Goodspeed, K., Haffner, D. N., Golla, S., Morris, M. A., & Evans, P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00023-4 · Cited by 2
Taurines, R., Gerlach, M., & Warnke, A. (2016) · Springer eBooks · doi:10.1007/978-3-662-48624-5_5 · Cited by 3
Алымов, А. А., Капица, И. Г., & Воронина, Т. А. (2021) · Neurochemical Journal · doi:10.1134/s1819712421020033 · Cited by 3
Laing, B. T., Anderson, M. S., Jayan, A., Park, A. S., Erbaugh, L. J., Solís, Ó., Wilson, D. J., Michaelides, M., & Aponte, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.06.506804 · Cited by 2
Yacoubi, F. A. E., Oukabli, M., Ibrahimi, A., Kisra, H., & Bensaid, M. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527323666230727102244 · Cited by 1
Neurobiological Factors of Executive Dysfunction in Autism Spectrum Disorders
Kozunova, G. L., Zakirov, F., Rytikova, A. M., Stroganova, T. A., & Chernyshev, B. (2023) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-023-01512-7 · Cited by 2
“In addition, serotonin reuptake inhibitor antidepressants reduce stereotypical and ritualized behavior in many adult patients with autism and improve results on neuropsychological tests of inhibitory control [Hollander et al., 2012].”
BackgroundIm, D. S. (2024) · Journal of Neurology and Neurobiology · doi:10.16966/2379-7150.191 · Cited by 1
Maneeton, P., Maneeton, B., Winichaikul, Y., Kawilapat, S., Kienngam, N., & Maneeton, N. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s465611 · Cited by 4
“12,13 Several antidepressants, including tricyclic antidepressants (TCAs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and SSRIs been shown to have an effect on SERT.”
BackgroundRealpe, A. X., Norris, J. E., Lorenc, A., Cotton, L., Morgan, Z. L., Sadik, A., Rai, D., Mills, N., Carmichael, D., Cochrane, M., et al. (2026) · Autism · doi:10.1177/13623613261466306 · Cited by 1
“Only three RCTs of SSRIs in autistic adults have been conducted to date (Buchsbaum et al., 2001; Hollander et al., 2012; McDougle et al., 1996), but they had small samples and a focus on repetitive behaviours rather than anxiety.”
Afsharnia, S., Liang, V., Lunsky, Y., Orsini, A., Tint, A., & Lin, H. (2025) · PLOS mental health. · doi:10.1371/journal.pmen.0000514 · Cited by 1
Novel therapeutics in autism spectrum disorder
Kevelson, S. D., Elmaghraby, R., Patel, F., Brown, H. R., Gorenstein, M., Bain, J., Grinspan, Z. M., Pedapati, E. V., Veenstra-VanderWeele, J. M., & Vandana, P. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00857 · Cited by 7
“Unfortunately, sizable studies of the SRIs citalopram [86] and fluoxetine [87] did not show significant benefit for repetitive behavior in children with a diagnosis of ASD, although one RCT in adults did show benefit for OCD symptoms in autistic adults [88].”
Stereotypic behaviors across species: From neurobiological mechanisms to farm animal welfare
Li, C., Gao, J., Shu, H., Zhao, G. S., & Gu, X. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106637 · Cited by 2
Measuring the Effects of Medication for Individuals with Autism
Zarcone, J. R., Griffith, A. K., & Rieken, C. J. (2018) · Springer eBooks · doi:10.1007/978-3-030-03213-5_5 · Cited by 1
Tiefgreifende Entwicklungsstörungen
Warnke, A., & Taurines, R. (2015) · Springer eBooks · doi:10.1007/978-3-642-45028-0_83-1 · Cited by 1
Stereotypies in Childhood Developmental Disorders and Neurodegenerative Diseases
Shahed, J. J. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197574317.003.0011 · Cited by 1
Idiopathic Autism Spectrum Disorder
Carroll, H. M., Thom, R. P., & McDougle, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-76269-7_1 · Cited by 1
Pharmacotherapy in autism spectrum disorder
Smile, S., & Anagnostou, E. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-03056-2_5 · Cited by 1
Self-citationPharmacobiological Treatments in Autism Spectrum Disorders
(2017) · International Journal of Current Research and Review · doi:10.7324/ijcrr.2017.9188 · Cited by 1
“come, although all the studies have been with small sample sizes, with potential risk of bias [16, 17].”
BackgroundPsychopharmacology of Autism Spectrum Disorder
Ozdemir, S., Keary, C. J., Joshi, G., Ceranoglu, A. T., & McDougle, C. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-46295-6_25 · Cited by 1
de Oliveira, C. A., Belmont, E. J., de Oliveira, I. A. V., Batista, M. M., Soares, M. D. C. R., & de Sousa, M. N. A. (2021) · ID on line REVISTA DE PSICOLOGIA · doi:10.14295/idonline.v15i56.3131 · Cited by 1
Tiefgreifende Entwicklungsstörungen
Warnke, A., & Taurines, R. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_83 · Cited by 1
Scahill, L. D., Tillberg, C. S., & Martin, A. (2014) · Wiley eBooks · doi:10.1002/9781118911389.hautc23 · Cited by 1
Counseling and Other Therapeutic Strategies for Children with AS and Their Families
Sharp, S. (2013) · Issues in children's and families' lives · doi:10.1007/978-1-4614-7016-8_3 · Cited by 1
López, V. H., & Osorio, M. D. P. P. (2015) · Repositorio Institucional E-DocUR (Universidad Del Rosario) · doi:10.48713/10336_10227
The content of serotonin cells in duodenal biopsies of autistic patients
Kazek, B., Jamroz, E., Kajor, M., Grzybowska‐Chlebowczyk, U., Ciupińska-Kajor, M., & Woś, H. (2013) · Pediatria Polska · doi:10.1016/j.pepo.2013.03.005
“[3] Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ.”
BackgroundResearch Progress of Serotonin in Autism Spectrum Disorders
王, 丽. (2015) · International Journal of Psychiatry and Neurology · doi:10.12677/ijpn.2015.43003
Duketis, E. (2014) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-013-0577-9
“Für das Erwachsenenalter liegen zwei RCT zur Behandlung dieser Symptome mit SSRI vor [46, 47].”
BackgroundPharmacotherapy of Attention-Deficit, Hyperactivity, and Impulsiveness in Autism Spectrum Disorder
Propper, L., & Halawa, N. (2016) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.2016.21.3.10
Colasanto, M. (2015) · TSpace (University of Toronto) · Cited by 2
Rendall, A. R. (2017) · OpenCommons at University of Connecticut (University of Connecticut)
Treatment-resistant Delusional Dysmorphophobia
Lavanya, L., Raman, K., Nambi, S., & Chandraleka, G. S. (2016) · Indian Journal of Private Psychiatry · doi:10.5005/jp-journals-10067-0035
Management and treatment of autism spectrum disorders
Simonoff, E. A. (2020) · doi:10.1093/med/9780198713005.003.0030
Gruen, R. L. (2021) · Springer eBooks · doi:10.1007/978-3-319-91280-6_102092
Stein, D. J. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108164313.030 · Cited by 1
Novel Therapeutic Targets to Treat Social Behavior Deficits in Autism and Related Disorders
Gould, G. G. (2014) · Defense Technical Information Center (DTIC) · doi:10.21236/ada612531
Taylor, E. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198827801.003.0009
Gruen, R. L. (2018) · Springer eBooks · doi:10.1007/978-1-4614-6435-8_102092-1
Deb, S. S., Roy, M., Limbu, B., & Bertelli, M. O. (2022) · Autism and child psychopathology series · doi:10.1007/978-3-030-88538-0_50 · Cited by 1
Positron Emission Tomography in the Neuroimaging of Autism Spectrum Disorder
Tan, Z., Ye, W., Xu, H., & Wang, L. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.106825
Raitez, S. R., Souza, T. P. D., Oliveira, R. T. D., Nascif, J. V. C., Culau, M. V., Teixeira, A. R., Orben, M. C., da Silva, F. D., Amaral, E. S., Brito, C. R., et al. (2023) · International Journal of Health Science · doi:10.22533/at.ed.15938923231010
Siafis, S., Çıray, O., Wu, H., Schneider‐Thoma, J., Bighelli, I., Krause, M., Rodolico, A., Ceraso, A., Deste, G., Huhn, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19311361
Siafis, S., Çıray, O., Wu, H., Schneider‐Thoma, J., Bighelli, I., Krause, M., Rodolico, A., Ceraso, A., Deste, G., Huhn, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19311373
NEUROBIOLOGICAL FACTORS OF EXECUTIVE DYSFUNCTION IN AUTISM SPECTRUM DISORDERS
Kozunova, G. L., Zakirov, F., Rytikova, A. M., Stroganova, T. A., & Chernyshev, B. (2023) · Журнал высшей нервной деятельности им И П Павлова · doi:10.31857/s0044467723020077
Chapter 66. Treatment of Autism Spectrum Disorder
Hegarty, J. P., & Hardan, A. Y. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as66
Ziel, Methoden und Anwendungsbereich der Leitlinie
Voderholzer, U., Rubart, A., Kathmann, N., Staniloiu, A., Kordon, A., & Zurowski, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-67878-7_1
Voderholzer, U., Rubart, A., Kathmann, N., Staniloiu, A., Kordon, A., & Zurowski, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-67878-7_6
Neurological evaluation and management of autism spectrum disorder
Goodspeed, K., Haffner, D. N., Golla, S., Morris, M. A., & Evans, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00042-x
Metadata
- Authors
- Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., Wasserman, S., Swanson, E., & Settipani, C.
- Affiliations
- Albert Einstein College of Medicine (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2012-03
- Volume
- 169
- Issue
- 3
- Pages
- 292-299
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2035017299
- Cited by
- 224
- References
- 25
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 18 · 2023: 15 · 2022: 20 · 2021: 13 · 2020: 13 · 2019: 17 · 2018: 18 · 2017: 14 · 2016: 12 · 2015: 21 · 2014: 25 · 2013: 16 · 2012: 6
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (U54MH066673, 1U54 MH-066673)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- fluoxetine, autism spectrum disorder, autistic adults, repetitive behavior, obsessive-compulsive symptoms, Yale-Brown Obsessive Compulsive Scale, Clinical Global Impression Scale, selective serotonin reuptake inhibitors, treatment response, drug tolerability
- MeSH terms
- Adolescent, Adult, Child, Child Development Disorders, Pervasive, Double-Blind Method, Female, Fluoxetine, Humans, Male, Middle Aged, Obsessive Behavior, Psychiatric Status Rating Scales, Severity of Illness Index, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Stereotypic Movement Disorder, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.